Home > Rheumatology > ACR 2021 > Spotlight on Rheumatoid Arthritis > Pre-existing heart failure affects safety of hydroxychloroquine in RA patients

Pre-existing heart failure affects safety of hydroxychloroquine in RA patients

Presented By
Dr Elvira D’Andrea, Brigham and Women’s Hospital, MA, USA
Conference
ACR 2021
Comparing methotrexate and hydroxychloroquine therapy for rheumatoid arthritis (RA) resulted in similar results for severe cardiovascular events or sudden cardiac death/ventricular arrhythmia. In case of a concomitant heart failure diagnosis, methotrexate appears to be a safer option in terms of mortality and cardiovascular events. “In the US, hydroxychloroquine is commonly used as a first-line treatment in patients with RA, while methotrexate is the recommended first-line disease-modifying antirheumatic drug (DMARD),” Dr Elvira D’Andrea (Brigham and Women’s Hospital, MA, USA) stated [1]. In the wake of assessments on hydroxychloroquine use in COVID-19 patients, concerns regarding cardiovascular safety have been raised [2]. “We conducted a comprehensive cardiovascular safety evaluation of hydroxychloroquine compared with methotrexate in patients with RA,” Dr D’Andrea explained the aim of the presented research [1]. Data from Medicare linked to the N...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on